AIIMS Delhi has resumed free Therapeutic Drug Monitoring (TDM) tests for epilepsy patients. This initiative reduces financial ...

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Patients with epilepsy may report less than half of their seizures to clinicians, according to survey results presented online as part of the 2020 American Academy of Neurology Science Highlights.

According to a recent study, in patients with frontotemporal dementia (FTD), epileptic seizures are significantly more common than previously known. The discovery deepens understanding of the symptoms ...

Patients with functional seizures had slightly better cognitive performance than those with epilepsy, but worse performance compared with a healthy cohort of patients, according to a systematic review ...

In this younger patient population, diazepam nasal spray was readily absorbed and demonstrated a consistent PK profile with that of older children and adults aged 6 to 59 years. The Food and Drug ...

—After ruling out seizure mimics and seizures caused by an acute trigger, the remaining patients with unprovoked seizure require a further assessment. Here are some details. Reviewed by Aaron Miller, ...

Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...

Erin McNabb tried drug after drug to control her epilepsy. Finally, one kept her seizure-free — but doctors prescribed a dose so high that she suffered memory loss, depression and other serious side ...

A “unique” AI-powered headset that can predict epileptic seizures minutes before they occur has been developed by scientists in Scotland. The Glasgow Caledonian University team behind the research say ...